1. Anderson LA. An update on the cause of abdominal aortic aneurysms. J Vasc
Nurs 1994;12:95–100 [review].
2. MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of
abdominal aortic aneurysm. Br J Surg 1994;81:935–41 [review].
3. Szuba A, Cooke JP. Thromboangiitis obliterans. An update on Buerger’s disease. West J Med 1998;168:255–60 [review].
4. Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 1988;27:41–9.
5. Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs 1996;10:78–86.
6. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 1990;82:173–7.
7. Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication—a double-blind, placebo-controlled study. J Intern Med 1992;231:261–7.
8. Van Rij AM, Solomon C, Packer SGK, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 1994;90:1194–9.
9. Zheng P. Traditional Chinese medicine anesthesia in severe thromboangiitis obliterans. Report of 30 cases. Chin Med J (Engl) 1988;101(3):221–4.
10. Yang BH, Zhang SG. Study of thromboangiitis obliterans treated with “vascular no. 3” using Doppler ultrasound. Chung Hsi I Chieh Ho Tsa Chih 1989;9:596–8, 581 [in Chinese].
11. Mishima Y, Kamiya K, Sakaguchi S, et al. A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion. Angiology 1977;28:84–94.
12. Stammler F, Diehm C, Hsu E, et al. The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically? Dtsch Med Wochenschr 1996;121:1417–23 [in German].
